.1 imol kg-' for PA-MTO and 4.5 Imol kg-' for pH-MTO. The concentrations of MTO were determined using high-performance liquid chromatography (HPLC) in blood, liver, heart, spleen and kidneys of the mice. Additionally, the toxicity and anti-tumour activity of MTO was evaluated in a xenograft model using a human LXFL 529/6 large-cell lung carcinoma. The dose administered was 90% of the maximum tolerated dose (MTD) of the corresponding formulation (8.1 Amol kg-' for free MTO, 12.1 iimol kg-' for PA-MTO and pH-MTO). The pharmacokinetic behaviour of PA-MTO in blood was faster than that of free MTO, but the cytotoxic effect was improved. In contrast, pH-MTO showed a tenfold increased area under the curve (AUC) in blood compared with free MTO, without improvement of the cytotoxic effect. This discrepancy between the pharmacokinetic and cytotoxic results could be explained by the fact that MTO in pH-MTO liposomes remains mainly in the vascular space, whereas MTO in PA-MTO liposomes is rapidly distributed into deep compartments, even more so than free MTO.
Mitoxantrone (MTO, Novantrone) or 1,4-dihydroxy-5,8-bis {{2-[(2-hydroxyethyl)-amino]ethyl}amino}-9,10-anthracenedione dihydrochloride is active against lymphomas, breast cancer, acute leukaemias and other malignancies (Shenkenberg and von Hoff, 1986 , Faulds et al, 1991 . The dose-limiting toxicity of M1O is myelosuppression, but cardiotoxicity may also occur. The risk of cardiomyopathy increases as the total cumulative dose of MiX increases, but it is considerably lower than that with the structurally related anthracyclines. An overall incidence of MTO-associated cardiac effect of 3% in adults and 6% in children has been reported (DuKart et al, 1985) ; the estimated worst-case incidence of congestive heart failure being 1.3% compared with 2.2% with doxorubicin. For the treatment of solid tumours, MTO is generally administered as a single short-time infusion every 3 weeks at a dose of 12-14 mg in-2.
Although MTO features structural similarities to doxorubicin and other DNA-intercalating agents, significant differences in the mechanism of action were found. At least three mechanisms were described: stabilization of the topoisomerase-DNA cleavable complex, which prevents rejoining of strand breaks; aggregation and compaction of DNA via electrostatic cross-linking interactions; and oxidative activation of MTO with free radical generation inducing non-protein-associated strand breaks (Alberts et al, 1985a; Blanz et al, 1991; Faulds et al, 1991) .
To improve the anti-tumour activity and to reduce toxicity of various other anthracyclines, liposomal formulations were prepared. With doxorubicin (Gabizon et al, 1992; Gabizon, 1993) , daunorubicin (Forssen et al, 1992) and epirubicin (Mayhew et al, 1992) , it was shown that because of changed pharmacokinetic behaviour (Gabizon et al, 1993) and changed tissue distribution (Forssen et al, 1992 ) the overall therapeutic index of these antitumour drugs could be improved.
Different techniques have been developed to incorporate hydrophilic drugs into liposomes. The first method uses a proton gradient to actively load the liposomes with the drug (Mayer et al, 1986) . By lowering the pH in the inner compartment of the liposomes, basic drugs diffuse along the pH gradient into the liposomes, where they interact with the corresponding counterions (e.g. sulphate, citrate) (Mayer et al, 1985; Madden et al, 1991; Gabizon, 1992) . The disadvantage of this 'remote loading' technique is the rather low stability of the drug and proton gradient. Another possibility to associate hydrophilic basic drugs with liposomes is to complex them with negatively charged components of the liposome membrane (Amselem et al, 1990; Schwendener et al, 1991) . A third technique involves the modification of hydrophilic drugs into lipophilic derivatives (prodrugs). These molecules are incorporated as lipophilic components into the liposomal membrane (Rahman et al, 1986; Rubas et al, 1986) .
Two different liposomal formulations were developed with MTO: the first formulation containing phosphatidic acid (PA) to which MTO was complexed (PA-MTO liposomes) (Schwendener et al, 1991) and the second using the 'remote loading' technique (pH-MTO liposomes) (Schwendener et al, 1994) . In addition to the different loading techniques of the liposomes with MTO, the pH-MTO liposomes contained poly (ethylene) glycol (PEG)-modified dipalmitoyl phosphatidylethanolamine (PEG(2000) -DPPE) to provide them with long circulating properties (Allen, 1989; Lasic et al, 1991; Gabizon et al, 1993) . In order to compare the pharmacokinetic parameters of these two liposomal formulations with the aqueous solution that is currently on the market, the concentrations of MTO were measured using high-performance liquid chromatography (HPLC) in blood, liver, heart, spleen and kidneys of mice after intravenous administration of the three formulations. Our 
pH-MTO liposomes (pH-MTO)
MTO was loaded into the aqueous inner compartment of preformed liposomes using a gradient of 10 pH units (Schwendener et al, 1994 (Rentsch et al, 1996) . All glassware was silanized using Sylon CT (5% dimethyldichlorosilane in toluene) from Supelco (Bellefonte, PA, USA). Briefly, homogenization of tissues (liver, spleen, heart, kidney) was performed with a potter on ice in a solution of 20% ascorbic acid in 0.1 M citrate buffer (pH 3.0). To 50 mg of tissue, 1 ml of buffer was added. An aliquot of 1 ml of a solution containing hexane sulphonic acid (0.01 mg ml-'), ascorbic acid (0.5 mg ml-') and ametantrone (0.08 mg ml-', AMT; Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, Rockville, MD, USA), as internal standard, was added to 1 ml of tissue homogenate or whole blood. After vortexing for 30 s, 1 ml of 0.1 M borate buffer (pH 9.5) and 300 pl of a 1 N sodium hydroxide solution were added and vortexed again for 30 s. Extraction was performed with 5 ml of dichloromethane on a horizontal shaker (Infors HT, Infors, Bottmingen, Switzerland) during 60 min at 150 r.p.m. After centrifugation for 15 min at 2800 g, the organic layer was separated and dried by evaporation (Rotavapor, Buchi, Flawil, Switzerland), and the residue was dissolved in 150 ptl of mobile phase.
Samples (92 p.l) were injected into a 250 x 4-mm Nucleosil C column (Macherey Nagel, Oensingen, Switzerland) using an autosampler (9100, Varian, Sunnyvale, CA, USA). The HPLC column was eluted with acetonitrile (33%) and 0.16 M ammonium formate buffer (67%) pH 2.7 at a flow of 1.0 ml min-'. Hexane sulphonic acid was added at a concentration of 0.25 M. MTO was quantitated by UV detection using a 9050 UV-VIS Detector (Varian, Sunnyvale, CA, USA) set at 658 nm. The linear range was 4-400 nmol 1-1 whole blood and 4-1400 nmol 1-1 tissue homogenate, and the coefficients of variation within-day and between-days were below 4.5% for whole blood and below 10% for tissue homogenates (Rentsch et al, 1996) .
Pharmacokinetic analysis
All animals were injected i.v. with the same amount of MTO of the respective formulation, irrespective of their body weight. In order to compare directly the pharmacokinetic parameters of the different pharmaceutical formulations, all measured concentrations of MTO were corrected to a dose of 4.5 ,umol per kg of body weight and the mean body weight of 27.3 g (standard deviation 2.5 g, n = 54). The concentrations of MTO in the different tissues analysed were corrected for the amount of MTO in the residual tissue blood (Allen, 1989; Khor and Mayersohn, 1991) . The area under the curve of drug concentration as a function of time (AUC) and the area under the moment curve (AUMC) were determined with the trapezoidal rule over a period of 24 h for all organs studied. In addition, AUC and AUMC were also determined for infinite time in the case of whole blood.
British Journal of Cancer (1997) Toxicity and anti-tumour activity in a human xenograft model For in vivo experiments, 6-to 8-week-old female athymic nude mice of NMRI genetic background were used. The evaluation of the anti-tumour activity was performed as described earlier (Schwendener et al, 1991) . Briefly, tumour slices of human LXFL 529/6 large-cell lung carcinoma were implanted s.c. into both flanks of the animals. The experiment was started after 3-6 weeks when the median tumour diameter had reached 6 mm and the mean body weight of the mice was 28.5 g (standard deviation 3.1 g, n = 12). At day 0, the mice were randomized into treatment groups and control groups each consisting of four mice, which resulted in eight tumours to be evaluated in each group. All compounds were injected as a single dose on day 1 at 90% of the maximal tolerated dose (MTD), which was 8.1 iimol kg-' for free MTO Figure 1 . Over the whole time of observation, concentrations of MTO were tenfold higher with pH-MTO than with free MTO and PA-MTO. The pharmacokinetic parameters, summarized in Table 1 , were calculated from these data with a non-compartmental model. As expected, the area under the curve was highest for pH-MTO, ninefold higher than that for free MTO and 22-fold higher than that for PA-MTO. Accordingly, the mean residence time for pH-MTO was threefold lower than that for free MTO and twofold lower than that for PA-MTO. The total clearance in pH-MTO was ninefold lower than that for free MTO and 20-fold lower than that for PA-MTO. The volume of the central compartment was smallest for pH-MTO, namely sevenfold lower than that for free MTO, and 17-fold lower than that for PA-MTO. Finally, the steady-state volume of distribution for pH-MTO was 29-fold lower than that for free MTO and 37-fold lower than that for PA-MTO.
Tissue distribution
For all three formulations, the amounts of MTO in whole blood, liver, spleen, heart and kidney were determined as described. Time profiles describing the percentage of the drug in each organ are represented in Figure 2A -C. Comparing identical time points, the amount of MTO being found in a single tissue was consistently higher than that detected in whole blood, with the exception of the 5-and 30-min time points for pH-MTO ( Figure 2C ). With all formulations, the highest amount of MTO was found in the kidneys. With free MTO and PA-MTO, the maximal concentrations in liver and kidneys were reached within 5 min and in spleen in the liver (14%) and less than 5% in the blood; for free MTO, the recovery was 75%, with the highest amount in the kidneys (36%), a considerable amount in the liver (25%) and only 11.7% in the blood. For all three formulations, the amount was low in the spleen (s 1.2%). For the quantitative comparison of the various organs, the relative AUC (24 h) with correction for organ weight was used. Again, for all three preparations the highest values were found in the kidneys, followed by the liver. In heart and spleen, values were below 5% in all cases. In whole blood, a value of 16% was found with pH-MTO compared with < 2% for the other two formulations. Comparison between the formulations showed that the relative AUC value in the kidneys was about 50% for the liposomal formulations and 70% for free MTO, whereas in the liver the relative AUC was higher for the liposomal preparations (42% and 33%) compared with free MTO (20%).
Toxicity and anti-tumour activity in a human xenograft model Toxicity During 21 days, the animals of the control group did not change their body weight, whereas all treated animals had a reduced body weight after the chemotherapy. The maximum tolerated dose (MTD) of free MTO in tumour-bearing nude mice was determined to be 9.0 itmol kg-', given i.v. on day 1. After 21 days, the mortality was 20% (one out of five mice) and the median loss of body weight was 8%. For PA-MTO, the MTD was found to be 13.5 jtmol kg-', given i.v. on day 1, resulting in a mortality of 0%
(none out of four mice) and a median body weight loss of 9% on
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Efficacy
The anti-tumour activity of the three formulations was tested in a LXFL 529/6 human xenograft model. The treatment groups received a single i.v. dose of 8.1 jtmol kg-' MTO with free MTO and 12.1 iimol kg-' MTO with PA-MTO and pH-MTO. In Figure  3 , the relative tumour volume of the LXFL 529/6 human xenograft is shown as a function of time after randomization of the mice. (Schwendener et al, 1994 ). and a mean body weight of 27.3 g for the pharmacokinetic analyses.
The highest blood concentrations over the whole time of observation could be determined after the administration of pH-MTO and, accordingly, a significantly larger AUC in blood was calculated than for the other two formulations. Therefore, pH-MTO would be expected to be the preparation with the best cytotoxic activity; the results of the human xenograft model shown in Figure 3 suggest otherwise. The apparent discrepancy can be explained by the pharmacokinetic behaviour of the three formulations. pH-MTO, 88% of the administered dose was found in blood 5 min after injection, the respective value for free MTO was 12% and for PA-MTO 4%. At steady state conditions, the volume of distribution of pH-MTO (11 ml) was still lower than the volume of total body water in mice (18 ml). Free MTO and PA-MTO exhibited a much larger V , indicating that MTO in these pharmaceutical formulations was accumulating in deep compartments. Another pharmacokinetic parameter which allowed interpretation of the divergent results of blood AUC and cytotoxicity was the mean residence time (MRT). It could be demonstrated that although the AUC in blood was much higher with pH-MTO, the MRT of pH-MTO was threefold decreased compared with free MTO. After the administration of pH-MTO, the cytostatic drug was found at high concentrations in blood, but it was not distributed into the different tissues in high quantities. Therefore, the cytotoxic effect on the tumour in the human xenograft model was lower than that observed for free MTO. With PA-MTO, blood levels were about tenfold lower than those determined for pH-MTO but, because of the better tissue penetration of MTO, cytotoxicity was superior. These results support the statement of Liliemark and Peterson (1991) that a higher plasma concentration does not necessarily correlate with a more pronounced cytotoxic effect. About 18% of the MTO dose administered in its free form is excreted in the faeces within 5 days and approximately 10% was recovered in the urine (Alberts et al, 1985a) . The fact that MTO is rapidly released from both liposome formulations after i.v. administration implies no changes in the excretion pattern with these pharmaceutical formulations.
In the tissues analysed, 5 min after the administration, the entire amount of MTO was recovered in the case of pH-MTO, threequarters of the dose were found with free MTO and only one quarter of the dose with PA-MTO (Table 2) . This indicates that MTO as free MTO and PA-MTO accumulated in other tissues that were not analysed. In human autopsy tissues, the highest amounts of MTO were found in thyroid, liver, heart, pancreas and spleen in patients with various tumours (Stewart et al, 1986) . Alberts et al (1985b) reported in their study on the disposition of MTO in cancer patients that MTO appeared to distribute into a deep tissue compartment from which it was slowly released. Roboz et al (1984) stated in a case report that MTO must be distributed in the visceral tissues. Batra et al (1986) (Figure 1 ). The small differences in the amount of MTO administered did not influence the distribution of MTO in the different tissues, as shown by others (Batra et al, 1986) .
Cardiotoxicity is the most important side-effect besides the dose-limiting haematological toxicity. After administration of liposomal MTO (either PA-MTO or pH-MTO), the relative AUC in heart tissue was slightly decreased compared with that determined for free MTO. Therefore, a reduced risk of cardiomyopathy can be expected after the administration of the liposomal formulations. The relative AUC in the spleen did not depend on the pharmaceutical formulation, indicating that no accumulation of MTO occurred after injection of the liposomal encapsulated drugs. In contrast, the relative AUC in liver tissue was remarkably increased with PA-MTO compared with free MTO and only slightly increased with pH-MTO. To explain this result, the coating of the liposomes must be considered. Poly(ethylene)glycol-modified dipalmitoyl phosphatidyl-ethanolamine (PEG(2000)-DPPE), the liposome coating used in pH-MTO, is able to significantly inhibit the uptake of the liposomes by the Kupffer cells in the liver (Lasic et al, 1991) . In contrast, the PA-MTO liposomes were uncoated and probably carrying negative surface charges and therefore more likely to be rapidly taken up by the mononuclear phagocytic system (MPS).
In conclusion, the pharmacokinetic and cytotoxic behaviour of MTO in mice was compared after administration of three pharmaceutical formulations. pH-MTO showed a tenfold increased AUC in blood compared with free MTO, without improvement of the cytotoxic effect. PA-MTO exhibited faster blood pharmacokinetics than free MTO, but it had an improved cytotoxic effect. This discrepancy between the pharmacokinetic and cytotoxic results could be explained by the fact that MTO in pH-MTO liposomes remained mainly in the vascular space, whereas MTO in PA-MTO liposomes was rapidly distributed into deep compartments, even more so than free MTO.
